MDACC Study No:2013-0062(2009-0493GYN) ( NCT No: NCT01091428)
Title:Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer
Principal Investigator:Robert Coleman
Treatment Agent:MLN8237; Paclitaxel
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of
MLN8237 (alisertib) and paclitaxel can help to control advanced ovarian,
fallopian tube, or peritoneal cancer. Researchers will compare the effects of
this combination to those of paclitaxel alone. The safety of the study drug
combination will also be studied.

MLN8237 is designed to block certain proteins that cause cancer cells to grow
and divide. This blocking may cause the cancer cells to die.

Paclitaxel is designed to block cancer cells from dividing, which may cause
them to die.
Hide details for General InformationGeneral Information

Disease Group:Breast; Fallopian Tube; Ovary; Peritoneum
Phase of Study:Phase II
Treatment Agents:MLN8237
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Millennium Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Coleman
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-3357
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults